Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab, paclitaxel, and carboplatin (TRAIN-2) for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive, locally advanced, inflammastory, or early stage breast cancer at high risk of recurrence in adult patients.
This is written in the approval document as:
Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.
Citation
Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2), 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/775-pertuzumab-trastuzumab-paclitaxel-and-carboplatin-therapy-train-2-.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab |